NICE prioritization board decisions published in July 2024

NICE recently introduced a new centralized approach to prioritizing topics for its guidance and a decision-making body - a prioritization board. In May 2024, a new NICE-wide topic prioritization manual was released, and a new specific webpage for topic prioritization was launched.

In July 2024, the decisions of the prioritization board were first published (from all board meetings since January 2024). Sixteen topics were prioritized, including the following:

• Digital platforms for cardiac rehabilitation (Health Technology Evaluation);
• Familial breast cancer (clinical guidelines);
• Robotic assisted surgery (Health Technology Evaluation, early value assessment);
• Extracorporeal membrane oxygenation (ECMO) for acute heart failure in adults (Interventional Procedures Guidance);
• Bladder cancer (clinical guidelines);

Twenty topics were not prioritized. Some examples are provided below:

• Surgical vessel sealing systems (as this is an established technology within the NHS; it may be appropriate for future consideration as a potential topic within the late-stage assessment);
• Bladder EpiCheck for the detection of bladder cancer recurrence (as this is not an area of high system priority; recently published European guidelines on this topic did not recommend the technology);
• Extracorporeal membrane oxygenation (ECMO) for severe acute respiratory failure in adults (as there was limited evidence available in this area and an update would unlikely change the recommendations. It was agreed that some editorial amendments could be made to the guidance and related maternity guidelines).

One topic was withdrawn: Optical coherence tomography for percutaneous coronary interventions (Interventional Procedures Guidance), as this is now standard practice with no safety concerns.

See the full details here and here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.